OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.07 USD +6.47% Intraday chart for OPKO Health, Inc. +20.22% -29.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029 MT
Opko Health Insider Bought Shares Worth $1,344,600, According to a Recent SEC Filing MT
Opko Health Insider Bought Shares Worth $514,093, According to a Recent SEC Filing MT
OPKO Health Prices $200 Million Convertible Senior Notes Offering MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Advance Pre-Bell Thursday MT
OPKO Health Launching Private Offering of $200 Million Convertible Senior Notes MT
Chart OPKO Health, Inc.
More charts
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.07 USD
Average target price
4.25 USD
Spread / Average Target
+297.20%
Consensus
  1. Stock
  2. Equities
  3. Stock OPKO Health, Inc. - Nasdaq
  4. News OPKO Health, Inc.
  5. Sector Update: Health Care Stocks Higher in Moderation